Got a PSMA PET Quadra Scan???
November 3, 2026 at 3:21 AM
Got a PSMA PET Quadra Scan???
10 years ago PSMA PET scans did not exist...
November 1, 2026 at 9:08 PM
10 years ago PSMA PET scans did not exist...
Despite a lack of responses in the phase 2 LASER trial, Praful Ravi, MB, BChir, MRCP, of @danafarber.bsky.social explains how the outcome could help inform future research with radioligand therapy in advanced RCC #kcsm #oncology www.onclive.com/view/lutetiu...
Lutetium Lu 177 Vipivotide Tetraxetan Yields No Responses in PSMA+ ccRCC | OncLive
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
www.onclive.com
November 3, 2026 at 3:59 PM
Despite a lack of responses in the phase 2 LASER trial, Praful Ravi, MB, BChir, MRCP, of @danafarber.bsky.social explains how the outcome could help inform future research with radioligand therapy in advanced RCC #kcsm #oncology www.onclive.com/view/lutetiu...
Chau, Biswas, Wagle, Maeder, Leapman, Yu, Bhattacharya: Spatial Atlas-Informed Loss Ensembles for Whole-Body PSMA PET/CT Metastasis Segmentation https://arxiv.org/abs/2610.40834 https://arxiv.org/pdf/2610.40834 https://arxiv.org/html/2610.40834
November 2, 2026 at 6:39 AM
Chau, Biswas, Wagle, Maeder, Leapman, Yu, Bhattacharya: Spatial Atlas-Informed Loss Ensembles for Whole-Body PSMA PET/CT Metastasis Segmentation https://arxiv.org/abs/2610.40834 https://arxiv.org/pdf/2610.40834 https://arxiv.org/html/2610.40834
Um dos principais alvos dessa tecnologia é a proteína PSMA, encontrada em maior quantidade nas células tumorais. Exames de PET conseguem mapear essas lesões, permitindo o uso de substâncias como o lutécio-177 para atingir a doença diretamente.
November 3, 2026 at 3:00 AM
Um dos principais alvos dessa tecnologia é a proteína PSMA, encontrada em maior quantidade nas células tumorais. Exames de PET conseguem mapear essas lesões, permitindo o uso de substâncias como o lutécio-177 para atingir a doença diretamente.
🚀 A targeted #EV strategy for #prostate #cancer!
#PSMA-engineered #EVs deliver #siADAM9 to inhibit tumor growth, #migration, and #stemness while enhancing #androgen-targeted #therapy.
A promising step toward precision EV therapeutics! 🧬
🔗 www.oaepublish.com/articles/evc...
@labogden.bsky.social
#PSMA-engineered #EVs deliver #siADAM9 to inhibit tumor growth, #migration, and #stemness while enhancing #androgen-targeted #therapy.
A promising step toward precision EV therapeutics! 🧬
🔗 www.oaepublish.com/articles/evc...
@labogden.bsky.social
November 3, 2026 at 2:32 AM
🚀 A targeted #EV strategy for #prostate #cancer!
#PSMA-engineered #EVs deliver #siADAM9 to inhibit tumor growth, #migration, and #stemness while enhancing #androgen-targeted #therapy.
A promising step toward precision EV therapeutics! 🧬
🔗 www.oaepublish.com/articles/evc...
@labogden.bsky.social
#PSMA-engineered #EVs deliver #siADAM9 to inhibit tumor growth, #migration, and #stemness while enhancing #androgen-targeted #therapy.
A promising step toward precision EV therapeutics! 🧬
🔗 www.oaepublish.com/articles/evc...
@labogden.bsky.social
Adıyaman’daki hastanede prostat kanserinde Ga-68 PSMA PET/BT ilk kez uygulandı
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
Adıyaman’daki hastanede prostat kanserinde Ga-68 PSMA PET/BT ilk kez uygulandı
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp Kliniği'nde uygulanan yöntemle prostat kanserinin vücuttaki…
haberdal.com
October 29, 2026 at 12:04 PM
Adıyaman’daki hastanede prostat kanserinde Ga-68 PSMA PET/BT ilk kez uygulandı
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
And the radiologist at a certain famous London hospital who reported that I had PSMA avidity in my coccyx...
...(spoiler alert: it was in my sacrum S4)
Really I do know what I'm talking about here...
...(spoiler alert: it was in my sacrum S4)
Really I do know what I'm talking about here...
November 1, 2026 at 9:14 PM
And the radiologist at a certain famous London hospital who reported that I had PSMA avidity in my coccyx...
...(spoiler alert: it was in my sacrum S4)
Really I do know what I'm talking about here...
...(spoiler alert: it was in my sacrum S4)
Really I do know what I'm talking about here...
adultos con CPRCm positivo para el antígeno de membrana específico de próstata (PSMA). Está disponible en España desde el 1 de enero de 2026, financiado e indicado en pacientes que han recibido tratamiento previo con inhibidores de la vía
November 2, 2026 at 7:37 AM
adultos con CPRCm positivo para el antígeno de membrana específico de próstata (PSMA). Está disponible en España desde el 1 de enero de 2026, financiado e indicado en pacientes que han recibido tratamiento previo con inhibidores de la vía
Adıyaman’daki hastanede prostat kanserinde Ga-68 PSMA PET/BT ilk kez uygulandı
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
Adıyaman’daki hastanede prostat kanserinde Ga-68 PSMA PET/BT ilk kez uygulandı
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp Kliniği'nde uygulanan yöntemle prostat kanserinin vücuttaki…
haberdal.com
October 29, 2026 at 12:04 PM
Adıyaman’daki hastanede prostat kanserinde Ga-68 PSMA PET/BT ilk kez uygulandı
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
Adıyaman Eğitim ve Araştırma Hastanesi'nde prostat kanserinin tanı, yayılım değerlendirmesi ve tedavi takibinde kullanılan Galyum-68 (Ga-68) PSMA PET/BT görüntülemesi ilk kez gerçekleştirildi.Hastanenin Nükleer Tıp…
New hope for metastatic prostate cancer! FDA-expanded approval means eligible patients can receive Pluvicto® earlier.
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
October 27, 2026 at 10:04 PM
New hope for metastatic prostate cancer! FDA-expanded approval means eligible patients can receive Pluvicto® earlier.
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
cáncer de próstata, que es el PSMA, casi en el 90% de las células, y por otro lado lleva pegado una molécula que en este caso es radioactiva. En el momento que actúa, libera su radiación sobre el núcleo de la célula tumoral y la mata.
November 2, 2026 at 7:37 AM
cáncer de próstata, que es el PSMA, casi en el 90% de las células, y por otro lado lleva pegado una molécula que en este caso es radioactiva. En el momento que actúa, libera su radiación sobre el núcleo de la célula tumoral y la mata.
How does PSMA PET fit into prostate cancer imaging and management?
Explore clinical foundations, interpretive challenges, and multidisciplinary applications in Applied Radiology's 3-part webinar series.
📅 Nov 12, 17 & 24
🔗 bit.ly/4ibZsV1
#PSMAPET #Radiology
Explore clinical foundations, interpretive challenges, and multidisciplinary applications in Applied Radiology's 3-part webinar series.
📅 Nov 12, 17 & 24
🔗 bit.ly/4ibZsV1
#PSMAPET #Radiology
October 28, 2026 at 11:00 AM
How does PSMA PET fit into prostate cancer imaging and management?
Explore clinical foundations, interpretive challenges, and multidisciplinary applications in Applied Radiology's 3-part webinar series.
📅 Nov 12, 17 & 24
🔗 bit.ly/4ibZsV1
#PSMAPET #Radiology
Explore clinical foundations, interpretive challenges, and multidisciplinary applications in Applied Radiology's 3-part webinar series.
📅 Nov 12, 17 & 24
🔗 bit.ly/4ibZsV1
#PSMAPET #Radiology
Radioligand Therapy market: $3.20B (2025) to $18.22B by 2035, a 19.0% CAGR. PSMA prostate cancer uptake and the alpha-emitter pipeline drive growth. North America leads. www.strategicrevenueinsights.com/industry/ra... #MarketResearch #Oncology
October 30, 2026 at 1:30 PM
Radioligand Therapy market: $3.20B (2025) to $18.22B by 2035, a 19.0% CAGR. PSMA prostate cancer uptake and the alpha-emitter pipeline drive growth. North America leads. www.strategicrevenueinsights.com/industry/ra... #MarketResearch #Oncology
Real-World Outcomes of PSMA-Targeted Therapy for mCRPC Affirmed in French Study
🔗📰 Read the full article: zurl.co/ZeeKk
🔗📰 Read the full article: zurl.co/ZeeKk
October 26, 2026 at 10:00 PM
Real-World Outcomes of PSMA-Targeted Therapy for mCRPC Affirmed in French Study
🔗📰 Read the full article: zurl.co/ZeeKk
🔗📰 Read the full article: zurl.co/ZeeKk
Nükleer tıp uzmanı Aksoy prostat kanserinde Lutesyum-177 PSMA tedavisini anlattı
Medical Point Gaziantep Hastanesi Nükleer Tıp Uzmanı Doç. Dr. Füsun Kökçü Aksoy, kanser tedavisinde kullanılan radyoaktif iyot, karaciğer tümörlerine yönelik radyonüklid tedaviler ve lutesyum uygulamaları hakkında…
Medical Point Gaziantep Hastanesi Nükleer Tıp Uzmanı Doç. Dr. Füsun Kökçü Aksoy, kanser tedavisinde kullanılan radyoaktif iyot, karaciğer tümörlerine yönelik radyonüklid tedaviler ve lutesyum uygulamaları hakkında…
Nükleer tıp uzmanı Aksoy prostat kanserinde Lutesyum-177 PSMA tedavisini anlattı
Medical Point Gaziantep Hastanesi Nükleer Tıp Uzmanı Doç. Dr. Füsun Kökçü Aksoy, kanser tedavisinde kullanılan radyoaktif iyot, karaciğer tümörlerine yönelik radyonüklid tedaviler ve lutesyum uygulamaları hakkında bilgi verdi. Aksoy, tedavi…
haberdal.com
October 27, 2026 at 11:23 AM
Nükleer tıp uzmanı Aksoy prostat kanserinde Lutesyum-177 PSMA tedavisini anlattı
Medical Point Gaziantep Hastanesi Nükleer Tıp Uzmanı Doç. Dr. Füsun Kökçü Aksoy, kanser tedavisinde kullanılan radyoaktif iyot, karaciğer tümörlerine yönelik radyonüklid tedaviler ve lutesyum uygulamaları hakkında…
Medical Point Gaziantep Hastanesi Nükleer Tıp Uzmanı Doç. Dr. Füsun Kökçü Aksoy, kanser tedavisinde kullanılan radyoaktif iyot, karaciğer tümörlerine yönelik radyonüklid tedaviler ve lutesyum uygulamaları hakkında…
Daniel Khalaf, MD, on patient-reported quality of life with docetaxel vs. lutetium-177-PSMA-617 in mCRPC from the CCTG PR21 trial. #ESMO26
Watch now: https://bit.ly/4zRF5n2
Watch now: https://bit.ly/4zRF5n2
October 25, 2026 at 6:46 PM
Daniel Khalaf, MD, on patient-reported quality of life with docetaxel vs. lutetium-177-PSMA-617 in mCRPC from the CCTG PR21 trial. #ESMO26
Watch now: https://bit.ly/4zRF5n2
Watch now: https://bit.ly/4zRF5n2
The landmark VISION trial led to the approval of 177Lu-PSMA-617 as a treatment for prostate cancer patients. Now, the first clinical results from from an early-access PSMA therapy program are in.
October 22, 2026 at 1:11 PM
The landmark VISION trial led to the approval of 177Lu-PSMA-617 as a treatment for prostate cancer patients. Now, the first clinical results from from an early-access PSMA therapy program are in.
#ATNM Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Pr…
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-to-highlight-first-in-human-phase-1-study-072cwfpnxvsh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-to-highlight-first-in-human-phase-1-study-072cwfpnxvsh.html?utm_source=stocktitan-bluesky&utm_medium=social
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
Actinium Pharmaceuticals (ATNM) will feature its first-in-human Phase 1 study of ATNM-400 at ESMO 2026, held October 23–27 in Madrid. The investigational radiotherapy targets HER3 rather than PSMA in metastatic castration-resistant prostate cancer, disease that has spread and resists testosterone-lowering treatment.The study combines Zirconium-89-labeled imaging with Actinium-225 treatment to assess safety and establish a recommended Phase 2 dose. Patients with positive imaging proceed to treatment every six weeks for up to four cycles. Enrollment includes patients with and without prior PSMA-directed therapy. Initial imaging results showed tumor uptake and retention through Day 7; the company described initial tolerability as encouraging. The ESMO presentation is a trial-in-progress ePoster, with additional study assessments covering radiation exposure, drug behavior in the body and antitumor activity.
www.stocktitan.net
October 23, 2026 at 12:00 PM
#ATNM Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Pr…
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-to-highlight-first-in-human-phase-1-study-072cwfpnxvsh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ATNM/actinium-pharmaceuticals-to-highlight-first-in-human-phase-1-study-072cwfpnxvsh.html?utm_source=stocktitan-bluesky&utm_medium=social
I am looking for some circulating tumor cell data. This is for high risk localized prostate cancer, where localized means no metastasis by PET-CT/PSMA. The only data I know of are in a 2025 preprint, pubmed id 40672470.
October 23, 2026 at 1:17 AM
I am looking for some circulating tumor cell data. This is for high risk localized prostate cancer, where localized means no metastasis by PET-CT/PSMA. The only data I know of are in a 2025 preprint, pubmed id 40672470.
Actinium to present #$ATNM 400 poster @ ESMO
*23-27Oct
*Ph1 study
*mCRPC
*HER3 targeting mAb bound to Ac-225
*Dose escalation & expansion study
*To establish Ph2 dose
*Madrid💃
tinyurl.com/4uehupwr
*23-27Oct
*Ph1 study
*mCRPC
*HER3 targeting mAb bound to Ac-225
*Dose escalation & expansion study
*To establish Ph2 dose
*Madrid💃
tinyurl.com/4uehupwr
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 :: Actinium Pharmaceuticals, Inc. (ATNM)
tinyurl.com
October 23, 2026 at 1:06 PM
Actinium to present #$ATNM 400 poster @ ESMO
*23-27Oct
*Ph1 study
*mCRPC
*HER3 targeting mAb bound to Ac-225
*Dose escalation & expansion study
*To establish Ph2 dose
*Madrid💃
tinyurl.com/4uehupwr
*23-27Oct
*Ph1 study
*mCRPC
*HER3 targeting mAb bound to Ac-225
*Dose escalation & expansion study
*To establish Ph2 dose
*Madrid💃
tinyurl.com/4uehupwr
The almost 4k patients in this program were older, more heavily pre-treated, and had more lymph node metastases and lower PSA than the VISION Trial patients. See how their results compared, and whether PSMA-targeted therapy is effective for mCRPC patients: jnm.snmjournals.org/content/67/1...
Real-World Outcomes of [177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains challenging to treat, especially after failure of standard therapies, such as androgen receptor pathway inhibitors and taxane-based chem...
jnm.snmjournals.org
October 22, 2026 at 1:11 PM
The almost 4k patients in this program were older, more heavily pre-treated, and had more lymph node metastases and lower PSA than the VISION Trial patients. See how their results compared, and whether PSMA-targeted therapy is effective for mCRPC patients: jnm.snmjournals.org/content/67/1...
